Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BlossomHill Therapeutics, Inc. (BLSM)

BlossomHill Therapeutics Q2 net loss widens to $23.8 million; IPO raised $168.3 million

Negative Impact 3 of 5 earnings Written later

BlossomHill Therapeutics reported a second-quarter 2026 net loss of $23.8 million, or $(8.75) per share, up from $13.2 million, or $(5.51) per share, a year earlier, as research and development and general and administrative expenses rose. The company said its August 2026 initial public offering brought in $168.3 million in gross proceeds, and that it expects its cash and IPO proceeds to fund operations into the second quarter of 2028.

Key points

  • Q2 2026 net loss was $23.8 million, or $(8.75) per share, versus $13.2 million, or $(5.51) per share, in Q2 2025.
  • R&D expenses rose to $21.4 million from $12.5 million; G&A expenses rose to $3.3 million from $1.6 million.
  • Cash and cash equivalents were $95.4 million at June 30, 2026; the August 2026 IPO sold 10,516,240 shares for $168.3 million gross.
  • The FDA granted Fast Track designation to BH-30643 for advanced EGFR C797S-positive NSCLC; an end-of-phase 1 meeting is planned for Q4 2026.

The filing

CompanyBlossomHill Therapeutics, Inc. (BLSM)
Form8-K, current report
Filed with the SECSep 18, 2026, 7:15 AM ET
Accession number0001193125-26-395031

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.